Correction: The effect of MemoVigor 2 on recent-onset idiopathic tinnitus: a randomized double-blind placebo-controlled clinical trial
Frontiers in Pharmacology · 07.05.2026 · 17
DOI: 10.3389/fphar.2026.1856536 ↗Kurz gefasst
Korrektur in der Zeitschrift Frontiers in Pharmacology, online erschienen am 07.05.2026. Verfasst von Dimitrios G Balatsouras und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Otorhinolaryngology, Tzaneio General Hospital, Piraeus, Greece. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Kein Abstract verfügbar.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Otorhinolaryngology, Tzaneio General Hospital, Piraeus, Greece.
- Department of Otorhinolaryngology, Medical School, Democritus University of Thrace, Komotini, Greece.
Zitieren
APA
Balatsouras, D. G., Papitsi, I., Koukoutsis, G., & Katotomichelakis, M. (2026). Correction: The effect of MemoVigor 2 on recent-onset idiopathic tinnitus: a randomized double-blind placebo-controlled clinical trial. Frontiers in Pharmacology, 17. https://doi.org/10.3389/fphar.2026.1856536
Vancouver
Balatsouras DG, Papitsi I, Koukoutsis G, Katotomichelakis M. Correction: The effect of MemoVigor 2 on recent-onset idiopathic tinnitus: a randomized double-blind placebo-controlled clinical trial. Frontiers in Pharmacology. 2026;17. doi:10.3389/fphar.2026.1856536
BibTeX
@article{Balatsouras2026,
author = {Balatsouras, Dimitrios G and Papitsi, Isidora and Koukoutsis, George and Katotomichelakis, Michael},
title = {Correction: The effect of MemoVigor 2 on recent-onset idiopathic tinnitus: a randomized double-blind placebo-controlled clinical trial},
journal = {Frontiers in Pharmacology},
year = {2026},
volume = {17},
doi = {10.3389/fphar.2026.1856536}
}
EUVIMED